A196170 Stock Overview
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
No risks detected for A196170 from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||₩47,600.00|
|52 Week High||₩99,000.00|
|52 Week Low||₩45,900.00|
|1 Month Change||-8.46%|
|3 Month Change||-1.45%|
|1 Year Change||-33.05%|
|3 Year Change||228.28%|
|5 Year Change||953.88%|
|Change since IPO||1,228.37%|
Recent News & Updates
ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability
We feel now is a pretty good time to analyse ALTEOGEN Inc.'s ( KOSDAQ:196170 ) business as it appears the company may...
|A196170||KR Biotechs||KR Market|
Return vs Industry: A196170 exceeded the KR Biotechs industry which returned -34.3% over the past year.
Return vs Market: A196170 underperformed the KR Market which returned -14.3% over the past year.
|A196170 Average Weekly Movement||7.2%|
|Biotechs Industry Average Movement||6.5%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.4%|
|10% least volatile stocks in KR Market||3.1%|
Stable Share Price: A196170 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: A196170's weekly volatility (7%) has been stable over the past year.
About the Company
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology.
ALTEOGEN Fundamentals Summary
|A196170 fundamental statistics|
Is A196170 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A196170 income statement (TTM)|
|Cost of Revenue||₩33.04b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-90.97|
|Net Profit Margin||-9.43%|
How did A196170 perform over the long term?See historical performance and comparison
Is ALTEOGEN undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A196170's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A196170's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A196170 is unprofitable, so we can't compare its PE Ratio to the KR Biotechs industry average.
PE vs Market: A196170 is unprofitable, so we can't compare its PE Ratio to the KR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A196170's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A196170 is overvalued based on its PB Ratio (14.9x) compared to the KR Biotechs industry average (3.4x).
How is ALTEOGEN forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A196170 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).
Earnings vs Market: A196170 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: A196170's is expected to become profitable in the next 3 years.
Revenue vs Market: A196170's revenue (34.9% per year) is forecast to grow faster than the KR market (9.7% per year).
High Growth Revenue: A196170's revenue (34.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A196170's Return on Equity is forecast to be low in 3 years time (13.6%).
How has ALTEOGEN performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A196170 is currently unprofitable.
Growing Profit Margin: A196170 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: A196170 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare A196170's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A196170 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20.1%).
Return on Equity
High ROE: A196170 has a negative Return on Equity (-3.76%), as it is currently unprofitable.
How is ALTEOGEN's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A196170's short term assets (₩212.2B) exceed its short term liabilities (₩12.4B).
Long Term Liabilities: A196170's short term assets (₩212.2B) exceed its long term liabilities (₩3.2B).
Debt to Equity History and Analysis
Debt Level: A196170 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A196170's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A196170 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A196170 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.2% each year
What is ALTEOGEN current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A196170's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A196170's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A196170's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A196170's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A196170 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Soon-Jae Park, Ph D., serves as the Chief Executive Officer of ALTEOGEN Inc. He has several years of experience in R&D of biomedicine. He served as the Executive Officer at BINEX Co., Ltd.He started w...
Experienced Management: A196170's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ALTEOGEN Inc.'s employee growth, exchange listings and data sources
- Name: ALTEOGEN Inc.
- Ticker: A196170
- Exchange: KOSDAQ
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩2.126t
- Shares outstanding: 42.64m
- Website: https://www.alteogen.com
Number of Employees
- ALTEOGEN Inc.
- 62, Yuseong-daero
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/12 00:00|
|End of Day Share Price||2022/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.